- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01057576
Safety and Efficacy Study of Tarragon on Insulin Action in Humans (5011)
The Effect of Artemisia Dracunculus L. on Insulin Sensitivity in Obese, Insulin-Resistant Human Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Artemisia dracunculus L., often called Russian tarragon, is a wild specie and a close relative of common cooking tarragon (known as French tarragon or Artemisia dracunculus sativa or dracunculoides). Artemisia and, more specifically, Artemisia dracunculus, have a storied history of medicinal use in humans, particularly for treatment of diabetes. The Artemisia dracunculus extract described in this project as PMI-5011 was originally identified from a screening of extracts for hypoglycemic activity in diabetic mice as the most promising candidate for the development of a nutritional supplement for diabetes. The active compounds in the preparation are believed to be members of the sesquiterpene, lactone or flavanoid groups, of which the Artemisia family is well known. Preliminary data from our laboratory suggests that PMI-5011 may have significant effects to improve carbohydrate metabolism by enhancing molecular events of insulin action in skeletal muscle.
PMI-5011 is an herbal botanical dietary supplement prepared from Artemisia dracunculus L. (Russian Tarragon) to help maintain normal blood glucose concentrations. PMI-5011 is an ethanolic extract from fresh herb grown in standardized hydroponic conditions for maximum consistency and nutritional content. Artemisia is a large family of herbs with a rich history of safe medicinal and culinary use. PMI-5011 is able to significantly decrease blood glucose concentrations in Streptozotocin-induced diabetic mice and in genetically diabetic KK-Ay mice. The preparation does not, however, decrease blood glucose concentrations in non-diabetic mice or rats. The historical use of the plant and its extract suggest that it is safe and its non-toxicity has been confirmed with acute and chronic toxicity studies and non-mutagenicity confirmed with AMES testing. PMI-5011 may have several modes of action leading to its ability to decrease blood glucose concentrations in diabetic animals, suggesting it is comprised of several different nutrients that act synergistically. Some in vitro activities of PMI-5011 include the modulation of GLP-1 binding to its receptor and the stimulation of insulin-mediated glucose uptake into cultured skeletal muscle cells. PMI-5011 also decreases the expression of PEPCK in the liver of diabetic animals and may decrease hepatic glucose output as a result. Recently, in an in vitro assay identified that PMI 5011 may have potent effects to reduce phosphastase activities and thereby promote insulin sensitivity.
The overall objective of the study was to evaluate the effect of a high does of PMI 5011 in obese insulin resistant, yet non-diabetic subjects. The study is a double-blind, randomized, placebo-controlled, pilot study in which subjects will be randomized to receive either placebo or PMI-5011 (4 500mg caps/TID) for a total of 3 weeks of treatment. Each subject will continue on the same dosage of PMI-5011 or matching placebo for the entire duration of treatment.
For this pilot trial, a precise technique (hyperinsulinemic-euglycemic clamps) will be used to assess insulin sensitivity.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
• Criteria for Inclusion
Men and women with obesity and meeting all criteria listed below will be included in the study:
- Subjects >30 years of age
- Subjects not currently treated with diabetes medication
- Fasting blood glucose at time of screening of less than 126mg/dl
- Subjects with a Body Mass Index (BMI) > 32 and <45.
Written Informed Consent obtained PRIOR to performing any screening tests or study procedures.
• Exclusion Criteria
- Subjects with a prior history of Type 2 diabetes.
- Women who are pregnant or who are lactating.
- Women of childbearing potential who are not using an effective method of birth control
- Type 1 diabetes.
- Subjects who are currently on thiazolidinediones (rosiglitazone or pioglitazone) or who have taken these agents in the previous 12 weeks.
- Subjects who are on concomitant therapy with glucocorticoids (except topical or inhalant glucocorticoids).
- Subjects with a history or evidence of significant gastrointestinal dysfunction
- Subjects who are taking concomitant therapy with medications known to be nephrotoxic, such as aminoglycosides, methicillin, and cyclosporin.
- Subjects who have evidence of clinically significant renal dysfunction or disease
- Subjects with clinically significant cardiovascular dysfunction and/or history
- Subjects who have evidence within the preceding 6 months of hepatic disease or dysfunction; hepatitis; jaundice; cirrhosis.
- Subjects with clinically significant pulmonary, neurologic, hematologic, immunologic, neoplastic or metabolic disease.
- Subjects with evidence or recurrence of malignancy within the past five years, other than excised basal cell carcinoma.
- Subjects for whom surgery is anticipated during the study period.
- Subjects with an history of substance abuse or alcoholism within the past 5 years, or significant psychiatric disorder that would interfere with the subject's ability to complete the study.
- Subjects who have donated blood during the month prior to study entry or planned during the study.
- Subjects who have participated in other studies using an investigational drug during the preceding 3 months.
- Subjects who are current smokers or have smoked within the previous 6 months. No smoking will be allowed during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
capsule, daily dosage
|
Experimental: PMI 5011
An experimental group randomized to PMI 5011
|
capsule, daily dosing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Insulin sensitivity
Time Frame: at study completion
|
at study completion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
plasma abundane of bioactives
Time Frame: at study completion
|
at study completion
|
Collaborators and Investigators
Investigators
- Principal Investigator: William T Cefalu, MD, Pennington Biomedical Research Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PBRC 26006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on An alcoholic extract of Artemisia dracunculus L.
-
Shandong Luye Pharmaceutical Co., Ltd.Unknown
-
Laboratorios Leti, S.L.Completed
-
Han Wha Pharma Co., Ltd.UnknownDiabetic ComplicationKorea, Republic of
-
CV TechnologiesCompletedCognition | Attention | Memory | Learning | Well-BeingCanada
-
Shanghai Children's HospitalShanghai Children's Medical Center; BioGaia AB; Suzhou University Affiliated...UnknownCrying Time in Colicky InfantsChina
-
Natural Wellness EgyptCompletedType2 Diabetes MellitusEgypt
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedObesity | Insulin ResistanceMexico
-
Federico II UniversityCompleted
-
Laboratorios Casen-Fleet S.L.U.Apices Soluciones S.L.; Asociacion Colaboracion Cochrane IberoamericanaUnknownPostmenopausal Women With Moderate Vasomotor SymptomsSpain
-
Karolinska University HospitalKarolinska Institutet; University of Witten/Herdecke; Ekhagastiftelsen; Regional... and other collaboratorsCompletedPancreatic CancerSweden